Leichner P K, Klein J L, Fishman E K, Siegelman S S, Ettinger D S, Order S E
Cancer Drug Deliv. 1984 Fall;1(4):321-8. doi: 10.1089/cdd.1984.1.321.
Results of dosimetric studies are reported for 30 patients with hepatoma and 5 patients with primary hepatic cholangiocarcinoma who received treatment with 131I-labeled polyclonal antibodies. Studies included liver and tumor volume computations from X-ray CT scans, in vivo quantitation of the activity of radiolabeled antibodies in hepatic tumors and normal liver tissue, and effective half-life measurements. Twenty-two patients with hepatoma were administered 131I-labeled polyclonal anti-ferritin. Five hepatoma patients, who were AFP-positive, were administered anti-alpha-fetoprotein (AFP). Three patients with AFP-positive hepatomas received both 131I-labeled anti-ferritin and anti-AFP in a bolus. The five cholangiocarcinoma patients were treated with 131I-labeled anti-carcinoembryonic antigen (CEA). For administered activities of 30 mCi on day 0 and 20 mCi on day 5, mean values of the radiation dose to hepatomas were approximately 1100 rads for anti-ferritin, 350 rads for anti-AFP, and 960 rads for the combination of anti-ferritin and anti-AFP. Polyclonal anti-ferritin has, therefore, become the antibody of choice in the treatment of hepatoma. The radiation dose to cholangiocarcinomas from 131I-labeled anti-CEA and administered activities of 20 mCi on day 0 and 10 mCi on day 5 was approximately 620 rads. Total-body irradiation for these injection schedules ranged from 30 to 50 rads.
报告了30例肝癌患者和5例原发性肝内胆管癌患者接受¹³¹I标记的多克隆抗体治疗的剂量学研究结果。研究包括通过X射线CT扫描计算肝脏和肿瘤体积、对肝肿瘤和正常肝组织中放射性标记抗体活性进行体内定量以及有效半衰期测量。22例肝癌患者接受了¹³¹I标记的多克隆抗铁蛋白治疗。5例甲胎蛋白（AFP）阳性的肝癌患者接受了抗甲胎蛋白（AFP）治疗。3例AFP阳性的肝癌患者一次性接受了¹³¹I标记的抗铁蛋白和抗AFP治疗。5例胆管癌患者接受了¹³¹I标记的抗癌胚抗原（CEA）治疗。对于第0天给予30mCi、第5天给予20mCi的给药活度，抗铁蛋白对肝癌的平均辐射剂量约为1100拉德，抗AFP为350拉德，抗铁蛋白和抗AFP联合使用为960拉德。因此，多克隆抗铁蛋白已成为肝癌治疗的首选抗体。¹³¹I标记的抗CEA在第0天给予20mCi、第5天给予10mCi的给药活度对胆管癌的辐射剂量约为620拉德。这些注射方案的全身辐射剂量在30至50拉德之间。
